Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer

Journal of Clinical Oncology

Volumn 29, Issue 10, 2011, Pages 1261-1270

  Hutchins, Gordon ^a   Southward, Katie ^a   Handley, Kelly ^a   Magill, Laura ^a   Beaumont, Claire ^a   Stahlschmidt, Jens ^a   Richman, Susan ^a   Chambers, Philip ^a   Seymour, Matthew ^a   Kerr, David ^a   Gray, Richard ^a   Quirke, Philip ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROURACIL; FOLINIC ACID;

ADULT; ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL (TOPIC); COLON; COLORECTAL CANCER; DISEASE MARKER; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; ONCOGENE K RAS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PYROSEQUENCING; RECTUM TUMOR; RISK ASSESSMENT; WILD TYPE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; ENGLAND; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; ODDS RATIO; PATIENT SELECTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 79953856354     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.1366     Document Type: Article

References (48)

1. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
3. Rakha EA, Ellis IO: Triple-negative/basal-like breast cancer: Review. Pathology 41:40-47, 2009
4. Ferlay J, Bray E, Pisani P, et al: GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase number 5, version 2.0. Lyon, France, IARC Press, 2004
5. QUASAR Collaborative Group: QUASAR: A randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients. Lancet 370:2020-2029, 2007
6. Melville A, Sheldon TA, Gray R, et al: Management of colorectal cancer. Quality in Health Care 7:103-108, 1998
7. Cunningham D, Atkin W, Lenz HJ, et al: Colorectal cancer. Lancet 375:1030-1047, 2010
8. Sargent D, Sobrero A, Grothey A, et al: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27:872-877, 2009
9. Benson AB, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004 (Pubitemid 41103700)
10. Marshall JL, Haller DG, de Gramont A, et al: Adjuvant therapy for stage II, and III colon cancer: Consensus report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res 1:146-154, 2007
11. Alter E, Phelip JM, Guilhot JN, et al: Adjuvant chemotherapy for stage II colon cancer: Influence of care structures' characteristics on a controversial clinical practice. Eur J Gastroenterol Hepatol 19:995-1001, 2007 (Pubitemid 350287407)
12. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006
13. Petersen VC, Baxter KJ, Love SB, et al: Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 51:65-69, 2002 (Pubitemid 34717746)
14. Morris EJA, Maughan NJ, Forman D, et al: Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 56:1419-1425, 2007 (Pubitemid 47517838)
15. Quirke P, Morris E: Reporting colorectal cancer. Histopathology 50:103-112, 2007 (Pubitemid 44953402)
16. Shepherd NA, Quirke P: Colorectal cancer reporting: Are we failing the patient? J Clin Pathol 50:266-267, 1997
17. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: Theoretical considerations and practical challenges. J Clin Oncol 27:4027-4034, 2009
18. Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50:113-130, 2007
19. Grady WM, Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079-1099, 2008
20. Lanza G, Gafa R, Santini A, et al: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 24:2359-2367, 2006 (Pubitemid 46630668)
21. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005 (Pubitemid 46224239)
22. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2010
23. Jover R, Zapater P, Castells A, et al: The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 45:365-373, 2009
24. Bertagnolli M, Niedzwiecki D, Cromption CC, et al: Microsatellite instability predicts improved reponse to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and leukaemia group B protocol 89803. J Clin Oncol 27:1814-1821, 2009
25. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
26. Scaltriti M, Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 12:5268-5272, 2006 (Pubitemid 44497237)
27. Heinemann V, Stintzing S, Kirchner T, et al: Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 35:262-271, 2009
28. Loriot Y, Mordant P, Deutsch E, et al: Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 6:528-534, 2009
29. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The multicenter "RASCAL" study. J Natl Cancer Inst 90:675-684, 1998
30. Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85:692-696, 2001
31. Bouzourene H, Gervaz P, Cerottini JP, et al: p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36:1008-1015, 2000 (Pubitemid 30316426)
32. Deng G, Bell I, Crawley S, et al: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191-195, 2004 (Pubitemid 38114179)
33. Ogino S, Nosho K, Kirkner GJ, et al: CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58:90-96, 2009
34. Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063-6069, 2005
35. Tol J, Nategaal ID, Punt CJA: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361:98-99, 2009
36. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
37. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplation or irinotecan: Results from the Focus trial. J Clin Oncol 27:5931-5937, 2009
38. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005 (Pubitemid 46211509)
39. Braun MS, Richman SD, Quirke P, et al: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 26:2690-2698, 2008
40. Ishikawa T, Fujita T, Suzuki Y, et al: Tumor specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res 63:5564-5572, 2003 (Pubitemid 37139879)
41. Peltomaki P: DNA mismatch repair and cancer. Mutat Res 488:77-85, 2001
42. Eveno C, Nemeth J, Soliman H, et al: Association between a high number of isolated lymph nodes in T1 to T4 N0M0 colorectal cancer and the microsatellite instability phenotype. Arch Surg 145:12-17, 2010
43. Soreide K, Nedrebo BS, Soreide JA, et al: Lymph node harvest in colon cancer: Influence of microsatellite instability and proximal tumor location. World J Surg 33:2695-2703, 2009
44. Walther A, Johnstone E, Swanton C, et al: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9:489-499, 2009
45. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti- epidermal growth factor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
46. Ward RL, Turner J, Williams R, et al: Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 207:377-384, 2005 (Pubitemid 43025685)
47. Loughrey MB, Waring PM, Tan A, et al: Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 6:301-310, 2007 (Pubitemid 47175009)
48. Lynch HT, de la Chapelle A: Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36:801-818, 1999 (Pubitemid 29520569)